导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.50% | 4027/4773 |
| 近一周 | -2.19% | 3546/5465 |
| 近一月 | 0.12% | 675/5421 |
| 近一季 | -7.87% | 2997/5231 |
| 近半年 | -16.54% | 4182/4920 |
| 近一年 | 0.16% | 2745/4394 |
| 近两年 | 45.70% | 1647/2954 |
| 近三年 | 15.94% | 1621/2253 |
| 成立以来 | 12.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.17% 3553/4961 |
-0.88% 3318/5312 |
- - |
- - |
| 2025 | 31.37% 1242/4813 |
-1.63% 2718/3635 |
11.46% 182/4076 |
7.49% 3446/4524 |
11.47% 163/4813 |
| 2024 | 8.42% 1556/3463 |
-5.78% 1950/2808 |
-2.22% 1156/3014 |
12.43% 2350/3129 |
4.68% 680/3463 |
| 2023 | -9.69% 1216/2656 |
1.15% 1630/2280 |
3.11% 112/2385 |
-9.94% 1912/2515 |
-3.85% 802/2655 |
| 2022 | -24.59% 1231/2207 |
-21.53% 1632/1919 |
3.81% 1087/2016 |
-7.01% 111/2113 |
-0.45% 1609/2208 |
| 2021 | 15.90% 292/1822 |
-17.30% 1197/1255 |
10.49% 459/1330 |
8.10% 166/1466 |
17.34% 42/1822 |
| 2020 | 83.10% 35/1250 |
0.74% 156/1028 |
13.25% 634/1067 |
34.14% 4/1164 |
19.65% 72/1184 |
| 2019 | 25.12% 607/1092 |
30.86% 227/754 |
-8.56% 598/804 |
4.04% 223/850 |
0.50% 883/918 |
| 2018 | -26.10% 369/834 |
- - |
- - |
- - |
-13.15% 511/691 |
| 2017 | -16.09% 568/714 |
- - |
- - |
- - |
- - |
| 2016 | -20.13% 441/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达中证军工(LOF)A VS. 长安沪深300非周期A(740101) |